"Histamine dihydrochloride(Ceplene) is developed to maintain the integrity of pivotal immune cells, in particular T cells and natural killer (NK) cells, in patients with cancer. Ceplene treatment aims at facilitating immune-mediated destruction of cancer cells, including leukemic cells, and also at improving the efficiency of T and NK cell-activating agents such as IL-2. Research regarding histamine, the active agent underlying Ceplene, and related clinical results has been the subject of more than 80 presentations at major scientific and clinical meetings, and has been published in more than 300 scientific and clinical articles."@en . . . . . . . . "histamine dihydrochloride"@en . "# Middleton M, Sarno M, Agarwala SS, Glaspy J, Laurent A, McMasters K, Naredi P, O'Day S, Whitman E, Danson S, Cosford R, Gehlsen K: Pharmacokinetics of histamine dihydrochloride in healthy volunteers and cancer patients: implications for combined immunotherapy with interleukin-2. J Clin Pharmacol. 2002 Jul;42(7):774-81. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12092744"@en . . . . . . . . . . . . . . . . . . . . . . . . . . "investigational"@en . . "Investigated for use/treatment in hepatitis (viral, C), leukemia (myeloid), melanoma, and renal cell carcinoma."@en . "A depressor amine derived by enzymatic decarboxylation of histidine. It is a powerful stimulant of gastric secretion, a constrictor of bronchial smooth muscle, a vasodilator, and also a centrally acting neurotransmitter."@en . .